PDCD1 and melanoma: We next explored the relationship between SPA17 expression levels and the response to anti-PD-L1 immunotherapy in a pan-cancer cohort, including kidney renal clear cell carcinoma and the expression levels of anti-PD1 in melanoma (Figures 5D–G).